Torazina

A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Torazina is not approved for use in the United States.

Oral

Agitation

Adult: 100-200 mg 4 times daily.

Elderly: Initially, 25 mg, may increase to 50 mg 4 times daily, if necessary.

Oral

Nausea and vomiting

Adult: 25-50 mg every 4-6 hr. May also be given via IM inj.

Parenteral

Agitation

Adult: 50 mg IM or slow IV inj (concentrations not >25 mg/ml), repeated if necessary after 6-8 hr.

Elderly: 25 mg administered IM.

Applies to the following strengths: 50 mg; 25 mg; 50 mg/mL; 25 mg/mL

Usual Adult Dose for:

• Agitated State

Usual Pediatric Dose for:

• Psychosis

Additional dosage information:

• Dose Adjustments
• Dialysis
• Other Comments

Usual Adult Dose for Agitated State

IM: 50-150 mg, depending on the degree of severity.

May give additional doses in 30 minutes up to a total of 300 mg. Once control is obtained, administer orally.

Oral or IM: 10-200 mg every 4-6 hours.

Usual Pediatric Dose for Psychosis

Child > 12 years:

Oral or IM: 10-25 mg every 4-6 hours.

Dose Adjustments

In less severe disturbances, adjust dose downward.

Dialysis

Torazina is not dialyzable.

Other Comments

The total daily dose should not exceed 1000 mg.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Torazina

• Torazina Side Effects
• During Pregnancy
• Drug Interactions
• 1 Review
• Drug class: phenothiazine antiemetics

Related treatment guides

• Agitated State
• Psychosis
• Schizophrenia

Use in patients hypersensitive to the active ingredient or other phenothiazines.

Use in patients in coma

Use in patients with bone marrow depression

Use in patients with phaeochromocytoma

Use during lactation

Do not use during pregnancy, especially during the first three months, unless there are compelling reasons.

The concomitant administration of this product with other medication such as central nervous system depressants (including alcohol and anaesthetics) or antihypertensives, anticholinergic or dopaminergic drugs may result in accentuation of their effects, while potentiation of action may also occur with monoamine oxidase inhibitors, antidepressants and analgesics. Torazina may impair the effects of anticonvulsants. Torazina may affect the control of diabetes. Undesirable anticholinergic effects can be enhanced by anti-parkinson or other anticholinergic drugs.

The concomitant administration of this product with myelosuppressive drugs (carbamazepine, co-trimoxazole, chloramphenicol, sulphonamides, pyralizone analgesics (e.g. azapropazone), penicillamine and cytotoxics) increases the risk of toxicity.

Lithium administration will result in an increased risk of extrapyramidal effects and the possibility of neurotoxicity.

Sotalol administration will result in an increased risk of ventricular arrhythmia.

Concomitant use of Torazina with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended. Examples include certain antiarrhythmics, such as those of Class 1A (such as quinidine, disopyramide and procainamide) and Class III (such as amiodarone, sotalol and dofetilide), certain antimicrobials (sparfloxacin, moxifloxacin, erythromycin IV), tricyclic antidepressants (such as amitriptyline), certain tetracyclic antidepressants (such as maprotiline), other neuroleptics (e.g. phenothiazines, pimozide, sertindole and haloperidol), certain antihistamines (such as terfenadine), cisapride, bretylium and certain antimalarials such as quinine and mefloquine. This list is not comprehensive.

Concurrent use of drugs causing electrolyte imbalance is not recommended. Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

See also:
What are the possible side effects of Torazina?

Torazina is a member of the phenothiazine group of drugs and the side effects associated with that group have been noted. These include drowsiness, sedation, dry mouth, nasal stuffiness. Other possible anticholinergic side effects are blurred vision, tachycardia, constipation and urinary hesitancy or retention when due to enlarged prostate.

Confusional states or epileptic fits can occur. Extrapyramidal symptoms and hyperpyrexia have been reported. Neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic dysfunction and altered consciousness) may occur with any neuroleptic.

Sexual function may be impaired. Agranulocytosis and transient leucopenia have rarely been reported. Allergic skin reactions and photosensitivity have also been reported.

Torazina rarely causes obstructive jaundice associated with stasis in biliary canaliculi. Torazina treatment should then be withdrawn and not given again. Transient abnormalities of liver function tests may occur without jaundice.

Some individuals may be susceptible to the drug in low dosage and show paradoxical effects of excitement, agitation or insomnia and other minor side effects. The elderly are particularly susceptible to side effects of Torazina, especially to the sedative, hypotensive and temperature regulation effects. These effects may be dose related.

Withdrawal symptoms, including nausea, vomiting, sweating, insomnia, recurrence of psychotic symptoms and involuntary movement disorders have been noted.

Phenothiazines can produce ECG changes with prolongation of QT interval and T-wave changes, ventricular arrhythmias (VF, VT (rare)), sudden unexplained death, cardiac arrest and Torsades de pointes have been reported

Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs – Frequency unknown